Prospect of nanomaterials as antimicrobial and antiviral regimen

Ashok Chakraborty; Anil Diwan; Jayant Tatake; Ashok Chakraborty; Anil Diwan; Jayant Tatake

doi:10.3934/microbiol.2023024

AIMS Microbiology

2023, Volume 9, Issue 3: 444-466. doi: 10.3934/microbiol.2023024

Previous Article Next Article

Review

Prospect of nanomaterials as antimicrobial and antiviral regimen

AllExcel, Inc, Shelton, CT 06484, USA

Received: 05 January 2023 Revised: 09 March 2023 Accepted: 17 April 2023 Published: 10 May 2023

In recent years studies of nanomaterials have been explored in the field of microbiology due to the increasing evidence of antibiotic resistance. Nanomaterials could be inorganic or organic, and they may be synthesized from natural products from plant or animal origin. The therapeutic applications of nano-materials are wide, from diagnosis of disease to targeted delivery of drugs. Broad-spectrum antiviral and antimicrobial activities of nanoparticles are also well evident. The ratio of nanoparticles surface area to their volume is high and that allows them to be an advantageous vehicle of drugs in many respects. Effective uses of various materials for the synthesis of nanoparticles impart much specificity in them to meet the requirements of specific therapeutic strategies. The potential therapeutic use of nanoparticles and their mechanisms of action against infections from bacteria, fungi and viruses were the focus of this review. Further, their potential advantages, drawbacks, limitations and side effects are also included here. Researchers are characterizing the exposure pathways of nano-medicines that may cause serious toxicity to the subjects or the environment. Indeed, societal ethical issues in using nano-medicines pose a serious question to scientists beyond anything.

Keywords:

Citation: Ashok Chakraborty, Anil Diwan, Jayant Tatake. Prospect of nanomaterials as antimicrobial and antiviral regimen[J]. AIMS Microbiology, 2023, 9(3): 444-466. doi: 10.3934/microbiol.2023024

Related Papers:

[1]	Warin Rangubpit, Sunan Kitjaruwankul, Panisak Boonamnaj, Pornthep Sompornpisut, R.B. Pandey . Globular bundles and entangled network of proteins (CorA) by a coarse-grained Monte Carlo simulation. AIMS Biophysics, 2019, 6(2): 68-82. doi: 10.3934/biophy.2019.2.68
[2]	Ken Takahashi, Takayuki Oda, Keiji Naruse . Coarse-grained molecular dynamics simulations of biomolecules. AIMS Biophysics, 2014, 1(1): 1-15. doi: 10.3934/biophy.2014.1.1
[3]	Tomohiro Yanao, Sosuke Sano, Kenichi Yoshikawa . Chiral selection in wrapping, crossover, and braiding of DNA mediated by asymmetric bend-writhe elasticity. AIMS Biophysics, 2015, 2(4): 666-694. doi: 10.3934/biophy.2015.4.666
[4]	Warin Rangubpit, Pornthep Sompornpisut, R.B. Pandey . Thermal-induced unfolding-refolding of a nucleocapsid COVN protein. AIMS Biophysics, 2021, 8(1): 103-110. doi: 10.3934/biophy.2021007
[5]	James C. L. Chow . Recent progress in Monte Carlo simulation on gold nanoparticle radiosensitization. AIMS Biophysics, 2018, 5(4): 231-244. doi: 10.3934/biophy.2018.4.231
[6]	Masoud Jabbary, Hossein Rajabi . High-resolution phantom of a nephron for radiation nephrotoxicity evaluation in biophysical simulations. AIMS Biophysics, 2022, 9(2): 147-160. doi: 10.3934/biophy.2022013
[7]	Nily Dan . Bilayer degradation in reactive environments. AIMS Biophysics, 2017, 4(1): 33-42. doi: 10.3934/biophy.2017.1.33
[8]	Zaynah Sheeraz, James C.L. Chow . Evaluation of dose enhancement with gold nanoparticles in kilovoltage radiotherapy using the new EGS geometry library in Monte Carlo simulation. AIMS Biophysics, 2021, 8(4): 337-345. doi: 10.3934/biophy.2021027
[9]	Carl S. Helrich . Studies of cholesterol structures in phospholipid bilayers. AIMS Biophysics, 2017, 4(3): 415-437. doi: 10.3934/biophy.2017.3.415
[10]	Wei Zhang, Sheng Cao, Jessica L. Martin, Joachim D. Mueller, Louis M. Mansky . Morphology and ultrastructure of retrovirus particles. AIMS Biophysics, 2015, 2(3): 343-369. doi: 10.3934/biophy.2015.3.343

Abstract

1. Introduction

The outbreak of COVID 19 pandemic has caused an urgent need to understand a wide range of issues, both basic and applied, from epidemiology to diverse multi-scale molecular structures of its constitutive elements of the novel coronavirus (CoV-2) and its interaction with surroundings [1]–[4]. The RNA genome of CoV-2 is believed to encode only four major structural, sixteen non-structural and eleven accessory proteins. The four structural proteins including spike (S) protein, nucleocapsid (N) protein, membrane (M) protein, and the envelope (E) protein are key components for viral transmission and reproduction [4]–[9]. The CoVE protein is the smallest with 76 amino acid residues (¹M²Y...⁷⁶V) (for sequence see https://www.uniprot.org/uniprot/P59637) [10] but plays an essential role in replication cycle of the virus such as formation of envelope as an integral membrane protein in viral assembly, budding and pathogenesis [4]–[16].

Very recently, Kuzmin et al. [17] have examined the conformational variability of CoVE protein in presence of a membrane environment using an all-atom MD along with a coarse-grained simulation. Because of ‘prohibitively long time’ with the atomistic simulation in ‘exhaustive sampling of the conformational space’ utility of coarse-grained approach implemented in this study is very well emphasized. They find that CoVE induces curvature in membrane and ‘it has a preferable position’ in already curved membranes with ‘the C-termini localize to the convex region’. Apart from locating specific segments of the protein from the membrane sites, there is no estimate of the overall size of the protein or the underlying dynamics. For example, how the segments of protein perform its stochastic moves and how the overall dynamics (diffusive, non-diffusive, drift etc.) of the protein (i.e. that of its center of mass) sets in as its segments settles in the curved region. How its conformation and dynamics depends on temperature. It may be useful to explore the structure and dynamics of a protein monomer free from membrane as a function of temperature first. Then incorporate the environment such as membrane and other constitutive elements such as solvent to assess its effect on the structure and dynamics. We would like to focus on the folding dynamics of a free CoVE protein, a purely theoretical exercise as an idealized model system, the characteristic of which may be useful in hypothesizing its role in interpreting the laboratory data. Such a basic investigation has not been performed to our knowledge as presented here.

Sequence of CoVE protein and its specific characteristics such as formation of membrane ion channel, virulence intensity, etc. and other proteins are studied in depth [4]–[16]. Three distinct segments of the CoVE protein start with the hydrophilic amino (N) terminal with about 10 residues (¹M–¹⁰G), followed by the hydrophobic transmembrane (TM) segment of about 25–27 residues (¹¹T–³⁷L), and ends with a relatively large hydrophilic carboxyl terminal consisting of the remaining residues (³⁸R–⁷⁶V). The structural details of how these segments interact, compete and cooperate is not fully known. The objective of this article is to investigate the effect of temperature on the structural dynamics by analyzing some of the local and global physical properties by a coarse-grained (CG) Monte Carlo simulation. The model and methods section is described in brief next followed by results and discussion and a conclusion.

2. Model and methods

2.1. Model

The model adopted here is based on an effective and efficient method involving bond-fluctuating mechanism on a discrete lattice with ample degrees of freedom to investigate complex issues in probing long time properties in polymer systems [18] that cannot be accessed by traditional MC or MD in a continuum space. This coarse-grained approach has been further developed over the years [19]–[21] with options to fine-grain and incorporate the specificity of amino acids to model proteins. The relevant detail has been already described to examine structural dynamics of a number of proteins [19]–[21]. In coarse-grained description, we constructed a CG protein model of CoVE containing a chain of 76 amino acid residues [10] in a specific sequence on a discrete cubic lattice with ample degrees of freedom to describe essential motion and fluctuation for each residue in the protein. A residue is modeled using a single CG node with a cubic node of size (2a)³ where a refers to the lattice constant. Consecutive nodes are tethered together by fluctuating covalent bonds of which the bond length between consecutive nodes varies between 2 and √(10) in unit of lattice constant (a). A generalized Lennard-Jones potential (U_ij) is used to describe the interaction between each residue and surrounding residues within a range (r_c) as:

$U_{i j} = [| ϵ_{i j} | {(\frac{σ}{γ_{i j}})}^{12} + ϵ_{i j} {(\frac{σ}{γ_{i j}})}^{6}], r_{i j} < r$ (1)

where r_ij is the distance between the amino acid residues at site i and j; r_c = √8 and σ = 1 in units of lattice constant. The potential strength e_ij in phenomenological interaction (1) is based on a knowledge-based [22] residue-residue contact matrix which has been developed over many years [23]–[27] from a huge (and rapidly growing) ensemble of protein structures in Protein Data Bank (PDB).

2.2. Methods

The protein chain is placed in a random configuration initially since one can reach any microstate from any other in the vast landscape of statistical ensemble in thermodynamic equilibrium—a fundamental principle of statistical physics. Therefore, starting configuration is irrelevant. Each residue undergoes its stochastic movement with the Metropolis algorithm. The protein configurations are thus generated by movements of each residue with a probability proportional to the Boltzmann factor exp(–ΔE/T) where ΔE is the change in energy between new and old configurations of the underlying residues subject to strictly imposed excluded volume constraints. Monte Carlo time step is defined by attempts to move each residue once. Simulation parameters i.e. length in unit of lattice constant are measured in arbitrary unit and the temperature T in reduced units of the Boltzmann constant.

It is important to point out that connecting the arbitrary units with the real sample size and temperature i.e. Kelvin, and time scale (micro-second) quantitatively is difficult due to phenomenological nature of the residue-residue interaction and the coarse-grained representation. Calibration of the parameters used in simulation requires measurements of some common physical quantities in both computer simulations as well as laboratory experiments which is not feasible. However, based on the approximate size of residue and its representation and response of the physical quantities with respect to changes in temperature, one can estimate the order of magnitude.

All simulations reported here are performed on a 150³ cubic lattice for a range of temperature T = 0.010–0.030 with 100 independent samples each with 10 million time steps; different sample sizes are also used to make sure that the qualitative results are independent of finite size effects. Both local and global physical quantities such as radius of gyration (R_g), root mean square displacement (RMSD) of the center of mass, structure factor (S), contact map, etc. are investigated as a function of reduced temperature. In the following ‘temperature’ refers to ‘reduced temperature’ and should not be confused with the absolute value.

3. Results and discussion

Snapshots of the protein (CoVE) at representative temperatures (T = 0.020, 0.024, 0.030) presented in Figure 1 illustrate the conformational changes as it denatures on raising the temperature. Obviously the protein conforms to a globular (compact) structure at low temperature (T = 0.020) and expands as it denatures (T = 0.030). The segmental globularity in the transmembrane segment of the protein is retained at least in part even at the high temperature (see below). Note that snapshots do not represent the average conformation; it is an illustrative mean that needs to be quantified. Therefore, some quantitative measures of segmental globularity are highly desirable. Average number (N_n) of residues within the range of interaction of each along the contour of the protein may provide some insight into the local restructuring as a function of temperature.

Figure 1. Snapshot of CoVE protein at the end of 10⁷ MCS time. Large black and grey sphere represents the first residue (¹M) and the last residue (⁷⁶V) of the protein, respectively. Smaller golden spheres represent the presence of other residues within the range of interaction excluding the consecutively connected residues. Backbone grey lines are covalent bonds connecting the residues. Snapshot at the left (T = 0.020), center (T = 0.024), right (T = 0.030) are at the representative temperatures to illustrate denaturing of the protein.

DownLoad: Full-Size Img PowerPoint

Figure 2. Residue contact profiles show average number (N_n) of surrounding residues around each residue of the protein within the range of interaction at a range of temperature (T = 0.012–0.024).

DownLoad: Full-Size Img PowerPoint

The contact profiles at representative temperatures are shown in Figure 2. At low temperatures (T = 0.012–0.020, in native phase), the coagulating centers are distributed sporadically particularly in N- and C-terminal regions along the backbone (e.g. ¹M²Y, ¹²L¹³I¹⁴V (in N-terminal), ⁵¹L⁵²V⁵³K, ⁵⁶V⁵⁷Y⁵⁸V⁵⁹Y, ⁷⁴L⁷⁵L⁷⁶V (in C-terminus)) with relatively large N_n. The transmembrane segment (¹⁸L–⁴⁴C), however, has the largest globular cluster with high number N_n of surrounding residues. Clearly, there is no significant change in contact profiles with the temperature in native phase. However, raising the temperature (T = 0.024) further leads to a substantial decrease in segmental globularity in both N- and C-terminals with low contact number N_n while retaining some globularity in TM segment with a relatively large N_n (see Figure 2). Thus, three distinct (N- and C-terminals separated by TM) segments can be identified easily from the evolution of contact profiles with the temperature.

The global structure and dynamics of the protein emerge from the stochastic movement of each residues and their configurational stabilities. Variation of the root mean square displacement of the center of mass (R_c) with the time step (t) at a range of temperature presented in Figure 3 show, how the asymptotic dynamics depends on the temperature. One can identify the type of dynamics by estimating the power-law exponent (ν) by fitting the data with a scaling, R_c ∝ t^ν where ν = ½ represents diffusion. Accordingly, the protein is found to move extremely slowly at low temperatures with ultra-sub-diffusive dynamics (i.e. ν = 0.05 at T = 0.020) and resumes diffusion at higher temperatures (i.e. ν = 0.47 at T = 0.024, see Figure 3). Dynamics do affect the conformation of the protein which can be quantified by analyzing radius of gyration and the structure factor (see below).

Figure 3. Average root mean square displacement (RMSD) of the center of mass (R_c) of the protein with the time step (t) versus temperature in range , T = 0.012–0.030 on a log-log scale. Slopes of the fitted data (solid black lines) in the asymptotic regime at a low (T = 0.012) and a high (T = 0.024) temperature are included with corresponding estimates.

DownLoad: Full-Size Img PowerPoint

How do we know that the protein chain has reached its steady-state equilibrium in 10 million time steps? It is important to check the convergence of physical quantities to make sure that system has reached steady-state within the range of simulation time steps in all such simulations. We have done here as in all our previous studies. For an illustration, variation of the radius of gyration with the time steps for a range of temperature is presented in Figure 4. We see that the radius of gyration has reached its steady-state equilibrium at almost all temperatures. It is not feasible to reach as good steady-state at low temperatures as is the case in most such interacting systems and even in laboratories. However, the probability of reaching the same asymptotic magnitude of R_g at all temperatures (T below 0.020) in sub-native phase (i.e. T = 0.018, 0.016 in Figure 4) is extremely low. Since it is not feasible to extend this simulation for such a long asymptotic time regime, it is worth issuing a caution to very cautious readers. The data on R_g in this sub-native phase (T = 0.010–0.020) in the following Figures should be therefore considered with caution.

Figure 4. Variation of the average radius of gyration (R_g) of the protein with the time step (t) for a temperature range, T = 0.016–0.030.

DownLoad: Full-Size Img PowerPoint

The radius of gyration (R_g) of the protein is a measure of its average size. Variation of the average (over configurations from 5 million to 10 million time steps each with 100 independent samples) radius of gyration (R_g) with the temperature (T) is presented in Figure 5. In contrast to denature phase (T = 0.020–0.030) where the radius of gyration (R_g) increases on raising the temperature, it decays on increasing the temperature in the native phase (T = 0.010–0.020). Why the protein contract on raising the temperature in sub-native phase? At very low temperatures, segmental interactions dominate over thermal noise. On raising the temperature, the frozen or frustrated trapped segments begin to explore and equilibrate better and therefore result into a more compact conformation. This process continues until a certain temperature beyond which thermal noise take over the segmental interactions with the temperature and protein begins to expand. Such an opposite thermal response in native and denature phases is also observed in other membrane proteins in recent years [20]. Based on a crude calibration of the measurements of the physical quantities with the same coarse-grained approach and an all-atom MD simulation [20], we believe that the range of temperature T = 0.020–0.030 may lie in the range of T = 300–400 K roughly. In order to claim such thermal response, a universal or sub-universal characteristics for the membrane proteins, more studies on many different membrane proteins are needed. The thermal response of the nucleocapsid protein (CoVN) of COVID 19 is also non-monotonic [21] but very different from that of CoVE. We hope this results will stimulate further investigations in this direction.

It is worth pointing out in passing that the validation of this model is based on the response of protein at extreme temperature where residue-residue interaction becomes irrelevant and conformation of a protein chain behaves similar to that of an athermal polymer chain. That is the case here as in all our previous work based on this coarse-grained model. Conformational dynamics of a range of proteins with various sizes are examined using this coarse-grained approach and observed different thermal response of proteins with comparable size. For example, proteins H3.1 and H2AX [19] are about the same size (136 and 140 residues) and exhibit very different thermal response to temperature: on raising the temperature, R_g of H3.1 increases continuously before saturation while R_g of H2AX increases to a maximum value followed by decay (a non-monotonic response different from the one observed here for CoVE). Thus, the specificity of residues and its distribution (i.e. sequence) in a protein pays a critical role in their collective response. Unfortunately, we do not have a data on a protein of the COVID related protein with the size comparable to CoVE to compare here. However, based on the analysis on many proteins (some cited in this study) with this approach, the conclusion on the thermal response of CoVE is reliable. A reader can always check it out by carry out simulation independently on an idealized model like the one presented here.

Figure 5. Average radius of gyration (R_g) of CoVE versus temperature.

DownLoad: Full-Size Img PowerPoint

Analysis of the structure factor can also provide insight into the global conformation of the protein. The structure factor (S(q)) is defined as:

$S (q) = {⟨ \frac{1}{N} {| \sum_{j = 1}^{N} e^{- i \vec{q} \cdot r_{j}} |}^{2} ⟩}_{| \vec{q} |}$ (2)

where r_j is the position of each residue. The magnitude of the wave vector (q) of wavelength λ is given by |q| = 2π/λ. Using a power-law scaling for the structure factor with the wave vector, S(q) ∝ q^–1/γ, one can evaluate the exponent γ. Variations of the structure factor with the wavelength (comparable to radius of gyration) is presented in Figure 5 for representative temperatures.

In general, the radius of gyration (R_g) of a polymer chain shows a power-law scaling with number (N) of monomer (residues), R_g ∝ N^x with a well-defined exponent x. Since a protein is a hetero-polymer chain of residues, one may use the same scaling law here for the protein with the radius of gyration comparable to wavelength (R_g ~ λ). Then the power-law exponent x = γ and one may be able to estimate the globularity index g which is the effective dimension (D) for the spread of the protein (g ≅ D). Since, N ∝ R_g^D, D = 1/γ. Higher magnitude of D represents more compact structure with higher degree of globularity. Note that this scaling analysis is an estimate and should not be taken as a precise measurement. Obviously D cannot be higher than 3, however high value indicates more compact conformations. Clearly, the protein remains globular (three dimensional) at low temperatures in native phase and it denatures into a ramified random coil (D ~ 2) structures at high temperatures (see Figure 6). It is important to point out that the such a vast changes in conformation of the protein in sub-native i.e. low temperature (T = 0.010–0.020) to native-to-denature phase i.e. at higher temperature regime (T = 0.020–0.030) may pose the possibility of COVE to be an intrinsically disordered protein at least in some range of temperature and time scales. For example, the segmental interactions in the native phase may be somewhat similar to interaction of a protein with its underlying environment e.g. a specific surface [28] even in the absence of explicit external surface.

Figure 6. Structure factor (S) of the protein versus wave length (lambda) at representative low and high temperatures. Data points are selected with wavelength comparable to radius of gyration of the protein at corresponding temperatures with the estimates of slopes. The number along the axes are the range of the axes (starting and end points).

DownLoad: Full-Size Img PowerPoint

4. Conclusions

Monte Carlo simulations are performed with a coarse-grained model of envelope membrane protein CoVE of the human coronavirus to assess its structural variability as a function of temperature. The evolution of the protein's conformation as a function of temperature is clearly seen in visualization via snapshots and animations. Segmental organizing of residues is quantified by examining local physical quantities such as average contact and mobility profiles as a function of temperature. From the variations in contact profiles as a function of temperature, it is feasible to identify three distinct segments (N-terminal and C-terminal separated by a transmembrane segment) which is consistent with the previous studies on CoVE [4],[5],[11]–[16]. The radius of gyration exhibits a non-monotonic thermal response: the protein CoVE contracts on heating in native phase and expands continuously on raising the temperature before reaching a saturation in denatured phase. Such a unique non-monotonic thermal response has been recently observed in other membrane proteins (unrelated to coronavirus). This may lead to speculate that thermal response may be a unique characteristic to identify different classes of proteins—obviously more studies are needed to confirm this observation. Thermal response of CoVE is different from another structural protein CoVN (a nucleocapsid protein) of the coronavirus [21]. Variation of the structure factor with the wave vector is studied in detail for a wide range of temperature. Scaling analysis of the structure factor provides a quantitative estimate of the overall globularity with an effective dimension (D). CoVE is found to remain globular (D ~ 3) in its native phase and unfolds continuously to a random coil (D ~ 2) conformation in denature phase on raising the temperature.

Acknowledgments

Thanks are due to Ms. Bethany Pond for her editorial assistance.

Conflict of interest

Authors Anil Diwan and Jayant Tatake are employed by the company NanoViricides, Inc, and they declare no conflicts of interest between the companies, AllExcel, Inc, TheraCour Pharma, Inc. and NanoViricides, Inc. The research was funded by NanoViricides, Inc.

References

[1]	Sethi S, Murphy TF (2001) Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 14: 336-363. https://doi.org/10.1128/CMR.14.2.336-363.2001
[2]	Durand ML, Calderwood SB, Weber DJ, et al. (1993) Acute bacterial meningitis in adults-A review of 493 episodes. N Engl J Med 328: 21-28. https://doi.org/10.1056/NEJM199301073280104
[3]	Lara HH, Ayala-Nu~nez NV, Ixtepan-Turrent L, et al. (2010) Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechno 8: 1-10. https://doi.org/10.1186/1477-3155-8-1
[4]	Singh SR, Krishnamurthy NB, Mathew BB (2014) A review on recent diseases caused by microbes. J Appl Environ Microbiol 2: 106-115.
[5]	Laxminarayan R, Duse A, Wattal C, et al. (2013) Antibiotic resistance—the need for global solutions. Lancet Infect Dis 13: 1057-1098. https://doi.org/10.1016/S1473-3099(13)70318-9
[6]	Friedman H, Newton C, Klein TW (2003) Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev 16: 209-219. https://doi.org/10.1128/CMR.16.2.209-219.2003
[7]	Atolani O, Baker MT, Adeyemi OS, et al. (2020) Covid-19: critical discussion on the applications and implications of chemicals in sanitizers and disinfectants. EXCLI J 19: 785-799.
[8]	Gurunathan S, Han JW, Kwon DN, et al. (2014) Enhanced antibacterial and antibiofilm activities of silver nanoparticles against Gram-negative and Gram-positive bacteria. Nanoscale Res Lett 9: 1-17. https://doi.org/10.1186/1556-276X-9-373
[9]	Yien L, Zin NM, Sarwar A, et al. (2012) Antifungal activity of chitosan nanoparticles and correlation with their physical properties. Int J Biomater 632698. https://doi.org/10.1155/2012/632698
[10]	Sobhani Z, Samani SM, Montaseri H, et al. (2017) Nanoparticles of chitosan loaded ciprofloxacin: fabrication and antimicrobial activity. Adv Pharmaceut Bull 7: 427. https://doi.org/10.15171/apb.2017.051
[11]	Rai A, Prabhune A, Perry CC (2010) Antibiotic mediated synthesis of gold nanoparticles with potent antimicrobial activity and their application in antimicrobial coatings. J Mater Chem 20: 6789-6798. https://doi.org/10.1039/c0jm00817f
[12]	Alshammari F, Alshammari B, Moin A, et al. (2021) Ceftriaxone mediated synthesized gold nanoparticles: A nano-therapeutic tool to target bacterial resistance. Pharmaceutics 13: 1896. https://doi.org/10.3390/pharmaceutics13111896
[13]	Cepas V, López Y, Gabasa Y, et al. (2019) Inhibition of bacterial and fungal biofilm formation by 675 extracts from microalgae and cyanobacteria. Antibiotics (Basel) 8: 77. https://doi.org/10.3390/antibiotics8020077
[14]	Cremonini E, Zonaro E, Donini M, et al. (2016) Biogenic selenium nanoparticles: characterization, antimicrobial activity and effects on human dendritic cells and fibroblasts. Microb Biotechnol 9: 758-771. https://doi.org/10.1111/1751-7915.12374
[15]	Haghighi F, Roudba Mohammadir S, Mohammadi P, et al. (2013) Antifungal acitivity of TiO₂ nanoparticles and EDTA on Candida abicans Biofilms. Infect Epidemiol Med 1: 133-138.
[16]	Singh P, Singh D, Sa P, et al. (2021) Insights from nanotechnology in COVID-19: prevention, detection, therapy and immunomodulation. Nanomedicine (Lond) 16: 1219-1235. https://doi.org/10.2217/nnm-2021-0004
[17]	Singh CK, Sodhi KK (2023) The emerging significance of nanomedicine-based approaches to fighting COVID-19 variants of concern: A perspective on the nanotechnology's role in COVID-19 diagnosis and treatment. Front Nanotechnol 4: 1084033. https://doi.org/10.3389/fnano.2022.1084033
[18]	Yang D (2021) Application of nanotechnology in the COVID-19 pandemic. Int J Nanomedicine 16: 623-649. https://doi.org/10.2147/IJN.S296383
[19]	Diwan A, Chakraborty A, Vijetha Chiniga V, et al. (2022) Dual effects of NV-CoV-2 biomimetic polymer: An antiviral regimen against COVID-19. PLOS One 17: e0278963. https://doi.org/10.1371/journal.pone.0278963
[20]	Chakraborty A, Diwan A, Arora V, et al. (2022) Mechanism of antiviral activities of nanoviricide's platform technology based biopolymer (NV-CoV-2). AIMS Public Health 9: 415-422. https://doi.org/10.3934/publichealth.2022028
[21]	Mubeen B, Ansar AN, Rasool R, et al. (2021) Nanotechnology as a novel approach in combating microbes providing an alternative to antibiotics. Antibiotics (Basel) 10: 1473. https://doi.org/10.3390/antibiotics10121473
[22]	Hung YP, Chen YF, Tsai PJ, et al. (2021) Advances in the application of nanomaterials as treatments for bacterial infectious diseases. Pharmaceutics 13: 1913. https://doi.org/10.3390/pharmaceutics13111913
[23]	Ozdal M, Gurkok S (2022) Recent advances in nanoparticles as antibacterial agent. ADMET DMPK 10: 115-129. https://doi.org/10.5599/admet.1172
[24]	Hussain FS, Abro NQ, Ahmed N, et al. (2022) Nano antivirals: A comprehensive review. Front Nanotechnol 4: 1064615. https://doi.org/10.3389/fnano.2022.1064615
[25]	Nami S, Aghebati-Maleki A, Aghebati-Maleki L (2021) Current applications and prospects of nanoparticles for antifungal drug delivery. EXCLI J 20: 562-584.
[26]	Khan I, Saeed K, Khan I (2017) Nanoparticles: properties, applications and toxicities. Arab J Chem 12: 908-931. https://doi.org/10.1016/j.arabjc.2017.05.011
[27]	Song X, Bayati P, Gupta M, et al. (2021) Fracture of magnesium matrix nanocomposites-a review. Int J Lightweight Mater Manufact 4: 67-98. https://doi.org/10.1016/j.ijlmm.2020.07.002
[28]	Vert M, Doi Y, Hellwich KH, et al. (2012) Terminology for biorelated polymers and applications (IUPAC Recommendations 2012). Pure Appl Chem 84: 377-410. https://doi.org/10.1515/amma-2016-0032
[29]	Von Nussbaum F, Brands M, Hinzen B, et al. (2006) Antibacterial natural products in medicinal chemistry—Exodus or revival?. Angew Chem Int Ed 45: 5072-5129. https://doi.org/10.1002/anie.200600350
[30]	Akhtar M, Swamy MK, Umar A, et al. (2015) Biosynthesis and characterization of silver nanoparticles from methanol leaf extract of Cassia didymobotyra and assessment of their antioxidant and antibacterial activities. J Nanosci Nanotechnol 15: 9818-9823. https://doi.org/10.1166/jnn.2015.10966
[31]	Fröhlich E, Salar-Behzadi S (2014) Toxicological assessment of inhaled nanoparticles: Role of in vivo, ex vivo, in vitro, and in silico studies. Int J Mol Sci 15: 4795-4822. https://doi.org/10.3390/ijms15034795
[32]	Qiu Y, Xu D, Sui G, et al. (2020) Gentamicin decorated phosphatidylcholine-chitosan nanoparticles against biofilms and intracellular bacteria. Int J Biol Macromol 156: 640-647. https://doi.org/10.1016/j.ijbiomac.2020.04.090
[33]	Evangelista TF, Andrade GR, Nascimento KN, et al. (2020) Supramolecular polyelectrolyte complexes based on cyclodextrin-grafted chitosan and carrageenan for controlled drug release. Carbohydr Polym 245: 116592. https://doi.org/10.1016/j.carbpol.2020.116592
[34]	Walvekar P, Gannimani R, Salih M, et al. (2019) Self-assembled oleylamine grafted hyaluronic acid polymersomes for delivery of vancomycin against methicillin resistant Staphylococcus aureus (MRSA). Colloids Surf B Biointerfaces 182: 110388. https://doi.org/10.1016/j.colsurfb.2019.110388
[35]	Ejaz S, Ihsan A, Noor T, et al. (2020) Mannose functionalized chitosan nanosystems for enhanced antimicrobial activity against multidrug resistant pathogens. Polym Test 91: 106814. https://doi.org/10.1016/j.polymertesting.2020.106814
[36]	Ucak S, Sudagidan M, Borsa BA, et al. (2020) Inhibitory effects of aptamer targeted teicoplanin encapsulated PLGA nanoparticles for Staphylococcus aureus strains. World J Microbiol Biotechnol 36: 69. https://doi.org/10.1007/s11274-020-02845-y
[37]	Vrouvaki I, Koutra E, Kornaros M, et al. (2020) Polymeric nanoparticles of pistacia lentiscus var. chia essential oil for cutaneous applications. Pharmaceutics 12: 353. https://doi.org/10.3390/pharmaceutics12040353
[38]	Gherasim O, Grumezescu AM, Grumezescu V, et al. (2020) Bioactive surfaces of polylactide and silver nanoparticles for the prevention of microbial contamination. Materials 13: 768. https://doi.org/10.3390/ma13030768
[39]	Grumezescu AM, Stoica AE, Dima-Balcescu MS, et al. (2019) Electrospun polyethylene terephthalate nanofibers loaded with silver nanoparticles: novel approach in anti-infective therapy. J Clin Med 8: 1039. https://doi.org/10.3390/jcm8071039
[40]	Khandelwal N, Kaur G, Kumara N, et al. (2014) Application of silver nanoparticles in viral inhibition: A new hope for antivirals. Dig J Nanomater Biostruct 9: 175-186. https://nanogo.co.uk/wp-content/uploads/2021/12/application-of-nanosilver.pdf
[41]	Alamdaran M, Movahedi B, Mohabatkar H, et al. (2018) In-vitro study of the novel nanocarrier of chitosan-based nanoparticles conjugated HIV-1 P24 protein-derived peptides. J Mol Liq 265: 243-250. https://doi.org/10.1016/j.molliq.2018.05.137
[42]	Belgamwar AV, Khan SA, Yeole PG (2019) Intranasal dolutegravir sodium loaded nanoparticles of hydroxypropyl-beta-cyclodextrin for brain delivery in Neuro-AIDS. J Drug Deliv Sci Technol 52: 1008-1020. https://doi.org/10.1016/j.jddst.2019.06.014
[43]	Costa AF, Araujo DE, Cabral MS, et al. (2018) Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis. Med Mycol 7: 52-62. https://doi.org/10.1093/mmy/myx155
[44]	Reddy YC (2018) Formulation and evaluation of chitosan nanoparticles for improved efficacy of itraconazole antifungal drug. Asian J Pharm Clin Res 11: 147-152. https://doi.org/10.22159/ajpcr.2018.v11s4.31723
[45]	Sombra FM, Richter AR, De Araújo AR, et al. (2020) Development of amphotericin B-loaded propionate Sterculia striata polysaccharide nanocarrier. Int J Biol Macromol 146: 1133-1141. https://doi.org/10.1016/j.ijbiomac.2019.10.053
[46]	Real D, Hoffmann S, Leonardi D, et al. (2018) Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations. PLOS One 13: e0207625. https://doi.org/10.1371/journal.pone.0207625
[47]	Durak S, Arasoglu T, Ates SC, et al. (2020) Enhanced antibacterial and antiparasitic activity of multifunctional polymeric nanoparticles. Nanotechnology 31: 175705. https://doi.org/10.1088/1361-6528/ab6ab9
[48]	Binder U, Aigner M, Risslegger B, et al. (2019) Minimal Inhibitory concentration (mic)-phenomena in candida albicans and their impact on the diagnosis of antifungal resistance. J Fungi (Basel) 5: 83. https://doi.org/10.3390/jof5030083
[49]	Kesharwani P, Fatima M, Singh V, et al. (2022) Itraconazole and difluorinated-curcumin containing chitosan nanoparticle loaded hydrogel for amelioration of onychomycosis. Biomimetics (Basel) 7: 206. https://doi.org/10.3390/biomimetics7040206
[50]	Butani D, Yewale C, Misra A (2016) Topical amphotericin B solid lipid nanoparticles: Design and development. Colloids Surf B 139: 17-24. https://doi.org/10.1016/j.colsurfb.2015.07.032
[51]	Souto E, Wissing S, Barbosa C, et al. (2004) Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 278: 71-7. https://doi.org/10.1016/j.ijpharm.2004.02.032
[52]	Cassano R, Ferrarelli T, Mauro MV, et al. (2016) Preparation, characterization and in vitro activities evaluation of solid lipid nanoparticles based on PEG-40 stearate for antifungal drugs vaginal delivery. Drug Deliv 23: 1037-46. https://doi.org/10.3109/10717544.2014.932862
[53]	Sanna V, Gavini E, Cossu M, et al. (2007) Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: In-vitro characterization, ex-vivo and in-vivo studies. J Pharm Pharmacol 59: 1057-64. https://doi.org/10.1211/jpp.59.8.0002
[54]	Bhalekar MR, Pokharkar V, Madgulkar A, et al. (2009) Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech 10: 289-96. https://doi.org/10.1208/s12249-009-9199-0
[55]	Jain S, Jain S, Khare P, et al. (2010) Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Deliv 17: 443-451. https://doi.org/10.3109/10717544.2010.483252
[56]	Kenechukwu FC, Attama AA, Ibezim EC (2017) Novel solidified reverse micellar solution-based mucoadhesive nano lipid gels encapsulating miconazole nitrate-loaded nanoparticles for improved treatment of oropharyngeal candidiasis. J Microencapsul 34: 592-609. https://doi.org/10.1080/02652048.2017.1370029
[57]	Mahato R, Tai W, Cheng K (2011) Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev 63: 659-70. https://doi.org/10.1016/j.addr.2011.02.002
[58]	Kumar R, Sinha VR (2016) Solid lipid nanoparticle: An efficient carrier for improved ocular permeation of voriconazole. Drug Dev Ind Pharm 42: 1956-67. https://doi.org/10.1080/03639045.2016.1185437
[59]	Füredi P, Pápay ZE, Kovács K, et al. (2017) Development and characterization of the voriconazole loaded lipid-based nanoparticles. J Pharm Biomed Anal 132: 184-9. https://doi.org/10.1016/j.jpba.2016.09.047
[60]	El-Housiny S, Shams Eldeen MA, El-Attar YA, et al. (2018) Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study. Drug Deliv 25: 78-90. https://doi.org/10.1080/10717544.2017.1413444
[61]	Anurak L, Chansiri G, Peankit D, et al. (2011) Griseofulvin solid lipid nanoparticles based on microemulsion technique. Adv Mater Res 197–198: 47-50. https://doi.org/10.4028/www.scientific.net/AMR.197-198.47
[62]	Ahmad A, Wei Y, Syed F, et al. (2016) Amphotericin B-conjugated biogenic silver nanoparticles as an innovative strategy for fungal infections. Microb Pathol 99: 271-81. https://doi.org/10.1016/j.micpath.2016.08.031
[63]	Tutaj K, Szlazak R, Szalapata K, et al. (2016) Amphotericin B-silver hybrid nanoparticles: Synthesis, properties and antifungal activity. Nanomedicine 12: 1095-103. https://doi.org/10.1016/j.nano.2015.12.378
[64]	Hussain MA, Ahmed D, Anwar A, et al. (2019) Combination therapy of clinically approved antifungal drugs is enhanced by conjugation with silver nanoparticles. Int Microbiol 22: 239-46. https://doi.org/10.1007/s10123-018-00043-3
[65]	Mussin JE, Roldán MV, Rojas F, et al. (2019) Antifungal activity of silver nanoparticles in combination with ketoconazole against Malassezia furfur. AMB Express 9: 131. https://doi.org/10.1186/s13568-019-0857-7
[66]	Souza AC, Nascimento AL, de Vasconcelos NM, et al. (2015) Activity and in vivo tracking of Amphotericin B loaded PLGA nanoparticles. Eur J Med Chem 95: 267-276. https://doi.org/10.1016/j.ejmech.2015.03.022
[67]	Vásquez Marcano RGDJ, Tominaga TT, Khalil NM, et al. (2018) Chitosan functionalized poly (ϵ-caprolactone) nanoparticles for amphotericin B delivery. Carbohydr Polym 202: 345-354. https://doi.org/10.1016/j.carbpol.2018.08.142
[68]	Chhonker YS, Prasad YD, Chandasana H, et al. (2015) Amphotericin-B entrapped lecithin/chitosan nanoparticles for prolonged ocular application. Int J Biol Macromol 72: 1451-8. https://doi.org/10.1016/j.ijbiomac.2014.10.014
[69]	Bhattacharjee S, Joshi R, Chughtai AA, et al. (2021) Graphene-and nanoparticle-embedded antimicrobial and biocompatible cotton/silk fabrics for protective clothing. ACS Appl Bio Mater 4: 6175-6185. https://doi.org/10.1021/acsabm.1c00508. 10.1021/acsabm.1c00508
[70]	Kharaghani D, Dutta D, Gitigard P, et al. (2019) Development of antibacterial contact lenses containing metallic nanoparticles. Polym Test 79: 106034. https://doi.org/10.1016/j.polymertesting.2019.106034
[71]	Kalita S, Kandimalla R, Bhowal AC, et al. (2018) Functionalization of β-lactam antibiotic on lysozyme capped gold nanoclusters retrogress MRSA and its persisters following awakening. Sci Rep 8: 1-13. https://doi.org/10.1038/s41598-018-22736-5
[72]	Konop M, Czuwara J, Kłodzińska E, et al. (2020) Evaluation of keratin biomaterial containing silver nanoparticles as a potential wound dressing in full-thickness skin wound model in diabetic mice. J Tissue Eng Regen Med 14: 334-346. https://doi.org/10.1002/term.2998
[73]	Gupta A, Briffa SM, Swingler S, et al. (2020) Synthesis of silver nanoparticles using curcumin-cyclodextrins loaded into bacterial cellulose-based hydrogels for wound dressing applications. Biomacromolecules 21: 1802-1811. https://doi.org/10.1021/acs.biomac.9b01724
[74]	Urbán P, Liptrott NJ, Bremer S (2019) Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies. Wiley Interdiscip Rev Nanomed Nanobiotechnol 11: e1546. https://doi.org/10.1002/wnan.1546
[75]	de la Harpe KM, Kondiah PPD, Choonara YE, et al. (2019) The hemocompatibility of nanoparticles: A review of cell-nanoparticle interactions and hemostasis. Cells 8: 1209. https://doi.org/10.3390/cells8101209
[76]	Guo S, Shi Y, Liang Y, et al. (2021) Relationship and improvement strategies between drug nanocarrier characteristics and hemocompatibility: What can we learn from the literature. Asian J Pharm Sci 16: 551-576. https://doi.org/10.1016/j.ajps.2020.12.002
[77]	Mikušová V, Mikuš P (2021) Advances in chitosan-based nanoparticles for drug delivery. Int J Mol Sci 22: 9652. https://doi.org/10.3390/ijms22179652
[78]	Pathak N, Singh P, Singh PK, et al. (2022) Biopolymeric nanoparticles based effective delivery of bioactive compounds toward the sustainable development of anticancerous therapeutics. Front Nutr 9: 963413. https://doi.org/10.3389/fnut.2022.963413
[79]	Chen HT, Neerman MF, Parrish AR, et al. (2004) Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J Am Chem Soc 126: 10044-10048. https://doi.org/10.1021/ja048548j
[80]	Jia YP, Ma BY, Wei XW, et al. (2017) The in vitro and in vivo toxicity of gold nanoparticles. Chin Chem Lett 28: 691-702. https://doi.org/10.1016/j.cclet.2017.01.021
[81]	Chetyrkina MR, Fedorov FS, Nasibulin AG (2022) In vitro toxicity of carbon nanotubes: a systematic review. RSC Adv 25: 16235-16256. https://doi.org/10.1039/D2RA02519A
[82]	Mahmoudi M, Hofmann H, Rothen-Rutishauser B, et al. (2012) Petri-Assessing the in vitro and in vivo Toxicity of Superparamagnetic Iron Oxide Nanoparticles. Chem Rev 112: 2323-2338. https://doi.org/10.1021/cr2002596
[83]	Chen L, Liu J, Zhang Y, et al. (2018) The toxicity of silica nanoparticles to the immune system. Nanomedicine 13: 1939-1962. https://doi.org/10.2217/nnm-2018-0076
[84]	Hadipour Moghaddam SP, Mohammadpour R, Ghandehari H (2019) In vitro and in vivo evaluation of degradation, toxicity, biodistribution, and clearance of silica nanoparticles as a function of size, porosity, density, and composition. J Control Release 311–312: 1-15. https://doi.org/10.1016/j.jconrel.2019.08.028
[85]	Zhang XF, Shen W, Gurunathan S (2016) Silver nanoparticle-mediated cellular responses in various cell lines: An in vitro model. Int J Mol Sci 17: 1603. https://doi.org/10.3390/ijms17101603
[86]	Yuan YG, Zhang S, Hwang JY, et al. (2018) Silver nanoparticles potentiates cytotoxicity and apoptotic potential of camptothecin in human cervical cancer cells. Oxid Med Cell Longev 18: 6121328. https://doi.org/10.1155/2018/6121328
[87]	Rim KT, Song SW, Kim HY (2013) Oxidative DNA damage from nanoparticle exposure and its application to workers' health: a literature review. Saf Health Work 4: 177-186. https://doi.org/10.1016/j.shaw.2013.07.006
[88]	Wen H, Dan M, Yang Y, et al. (2017) Acute toxicity and genotoxicity of silver nanoparticle in rats. PLOS One 2: e0185554. https://doi.org/10.1371/journal.pone.0185554
[89]	Hassanen EI, Khalaf AA, Tohamy AF, et al. (2019) Toxicopathological and immunological studies on different concentrations of chitosan-coated silver nanoparticles in rats. Int J Nanomedicine 14: 4723-4739. https://doi.org/10.2147/IJN.S207644
[90]	Panyam J, Labhasetwar V (2003) Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55: 329-347. https://doi.org/10.1016/S0169-409X(02)00228-4
[91]	Almofti MR, Ichikawa T, Yamashita K, et al. (2003) Silver ion induces a cyclosporine a-insensitive permeability transition in rat liver mitochondria and release of apoptogenic cytochrome C. J Biochem 134: 43-49. https://doi.org/10.1093/jb/mvg111
[92]	Iancu SD, Albu C, Chiriac L, et al. (2020) Assessment of gold-coated iron oxide nanoparticles as negative T2 contrast agent in small animal MRI studies. Int J Nanomedicine 4811–4824. https://doi.org/10.2147/IJN.S253184
[93]	Akhlaghi N, Najafpour-Darzi G (2021) Manganese ferrite (MnFe₂O₄) Nanoparticles: From synthesis to application-A review. J Ind Eng Chem 103: 292-304. https://doi.org/10.1016/j.jiec.2021.07.043
[94]	Ganapathe LS, Mohamed Md A, Yunus RM (2020) Magnetite (Fe₃O₄) Nanoparticles in biomedical application: from synthesis to surface functionalisation. Magnetochemistry 6: 68. https://doi.org/10.3390/magnetochemistry6040068
[95]	Liu Z, Liu Y, Liu S, et al. (2021) The effects of TiO₂ nanotubes on the biocompatibility of 3D printed Cu-bearing TC4 alloy. Mater Des 207: 109831. https://doi.org/10.1016/j.matdes.2021.109831
[96]	Andrade RGD, Ferreira D, Veloso SRS, et al. (2022) Synthesis and cytotoxicity assessment of citrate-coated calcium and manganese ferrite nanoparticles for magnetic hyperthermia. Pharmaceutics 14: 2694. https://doi.org/10.3390/pharmaceutics14122694
[97]	Rudramurthy GR, Swamy MK, Sinniah UR, et al. (2016) Nanoparticles: alternatives against drug-resistant pathogenic microbes. Molecules 21: 836. https://doi.org/10.3390/molecules21070836
[98]	Shiri S, Abbasi N, Alizadeh K, et al. (2019) Novel and green synthesis of a nanopolymer and its use as a drug delivery system of silibinin and silymarin extracts in the olfactory ensheathing cells of rats in normal and high-glucose conditions. RSC Adv 9: 38912-38927. https://doi.org/10.1039/C9RA05608D
[99]	Sharma S, Sudhakara P, Singh J, et al. (2021) Critical review of biodegradable and bioactive polymer composites for bone tissue engineering and drug delivery applications. Polymers (Basel) 13: 2623. https://doi.org/10.3390/polym13162623
[100]	Makadia HK, Siegel SJ (2011) Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 3: 1377-1397. https://doi.org/10.3390/polym3031377
[101]	Félix Lanao RP, Jonker AM, Wolke JG, et al. (2013) Physicochemical properties and applications of poly(lactic-co-glycolic acid) for use in bone regeneration. Tissue Eng Part B Rev 19: 380-390. https://doi.org/10.1089/ten.teb.2012.0443
[102]	da Silva D, Kaduri M, Poley M, et al. (2018) Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems. Chem Eng J 340: 9-14. https://doi.org/10.1016/j.cej.2018.01.010
[103]	Ramos DP, Sarjinsky S, Alizadehgiashi M, et al. (2019) Polyelectrolyte vs polyampholyte behavior of composite chitosan/ gelatin films. ACS Omega 4: 8795-8803. http://pubs.acs.org/journal/acsodf
[104]	Olasehinde TA, Olaniran AO (2022) Neurotoxicity of polycyclic aromatic hydrocarbons: a systematic mapping and review of neuropathological mechanisms. Toxics 10: 417. https://doi.org/10.3390/toxics10080417
[105]	Liu Y, Hardie J, Zhang X, et al. (2017) Effects of engineered nanoparticles on the innate immune system. Semin Immunol 34: 25-32. https://doi.org/10.1016/j.smim.2017.09.011
[106]	Corbo C, Molinaro R, Parodi A, et al. (2016) The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine (Lond) 11: 81-100. https://doi.org/10.2217/nnm.15.188
[107]	Suk JS, Xu Q, Kim N, et al. (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99: 28-51. https://doi.org/10.1016/j.addr.2015.09.012
[108]	Tan X, Fang Y, Ren Y, et al. (2019) D-α-tocopherol polyethylene glycol 1000 succinate-modified liposomes with an siRNA corona confer enhanced cellular uptake and targeted delivery of doxorubicin via tumor priming. Int J Nanomedicine 14: 1255-1268. https://doi.org/10.2147/IJN.S191858
[109]	Neophytou CM, Mesaritis A, Gregoriou G, et al. (2019) d-a-Tocopheryl Polyethylene Glycol 1000 Succinate and a small-molecule Survivin suppressant synergistically induce apoptosis in SKBR3 breast cancer cells. Sci Rep 9: 14375. https://doi.org/10.1038/s41598-019-50884-9
[110]	Dang Y, Guan J (2020) Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater Med 1: 10-19. https://doi.org/10.1016/j.smaim.2020.04.001
[111]	Adepu S, Ramakrishna S (2021) Controlled drug delivery systems: current status and future directions. Molecules 26: 5905. https://doi.org/10.3390/molecules26195905
[112]	Yu B, Tai HC, Xue W, et al. (2010) Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol 27: 286-298. https://doi.org/10.3109/09687688.2010.521200
[113]	Yu H, Yang Z, Li F, et al. (2020) Cell-mediated targeting drugs delivery systems. Drug Deliv 27: 1425-1437. https://doi.org/10.1080/10717544.2020.1831103
[114]	Zhao Z, Ukidve A, Kim J, et al. (2020) Targeting strategies for tissue-specific drug delivery. Cell 181: 2020. https://doi.org/10.1016/j.cell.2020.02.001
[115]	Manzari MT, Shamay Y, Kiguchi H, et al. (2021) Targeted drug delivery strategies for precision medicines. Nat Rev Mater 6: 351-370. https://doi.org/10.1038/s41578-020-00269-6
[116]	Mitchell MJ, Billingsley MM, Haley RM, et al. (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 20: 101-124. https://doi.org/10.1038/s41573-020-0090-8
[117]	Xie J, Lee S, Chen X (2010) Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 62: 1064-1079. https://doi.org/10.1016/j.addr.2010.07.009
[118]	Chatterjee DK, Diagaradjane P, Krishnan S (2011) Nanoparticle-mediated Hyperthermia in Cancer Therapy. Ther Deliv 2: 1001-1014. https://doi.org/10.4155/tde.11.72
[119]	Jacque D, Martínez Maestro L, del Rosal B, et al. (2014) Nanoparticles for photothermal therapies. Nanoscale 6: 9494-9530. https://doi.org/10.1039/C4NR00708E
[120]	Zhou Y, Quan G, Wu Q, et al. (2018) Mesoporous silica nanoparticles for drug and gene delivery. Acta Pharmaceutica Sinica B 8: 165-177. https://doi.org/10.1016/j.apsb.2018.01.007
[121]	Li Z, Barnes JC, Bosoy A, et al. (2012) Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev 41: 2590-2605. https://doi.org/10.1039/c1cs15246g
[122]	De Jong WH, Borm PJ (2008) Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine 3: 133-149. https://doi.org/10.2147/IJN.S596
[123]	Patra JK, Das G, Fraceto LF, et al. (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16: 71. https://doi.org/10.1186/s12951-018-0392-8
[124]	Masarudin MJ, Cutts SM, Evison BJ, et al. (2015) Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: application to the passive encapsulation of [(14)C]-doxorubicin. Nanotechnol Sci Appl 8: 67-80. https://doi.org/10.2147/NSA.S91785
[125]	Ajdary M, Moosavi MA, Rahmati M, et al. (2018) Health concerns of various nanoparticles: a review of their in vitro and in vivo toxicity. Nanomaterials (Basel) 8: 634. https://doi.org/10.3390/nano8090634
[126]	Ray P, Haideri N, Haque I, et al. (2021) The impact of nanoparticles on the immune system: a gray zone of nanomedicine. J Immunological Sci 5: 19-33. https://doi.org/10.29245/2578-3009/2021/1.1206
[127]	Abdal Dayem A, Hossain MK, Lee SB, et al. (2017) The role of reactive oxygen species (ros) in the biological activities of metallic nanoparticles. Int J Mol Sci 18: 120. https://doi.org/10.3390/ijms18010120
[128]	Ray PC, Yu H, Fu PP (2009) Toxicity and environmental risks of nanomaterials: challenges and future needs. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 27: 1-35. https://doi.org/10.1080/10590500802708267
[129]	Egbuna C, Parmar VK, Jeevanandam J, et al. (2021) Toxicity of nanoparticles in biomedical application: nanotoxicology. J Toxicol 2021:9954443: 1-21. https://doi.org/10.1155/2021/9954443
[130]	Huang YW, Cambre M, Lee HJ (2017) The toxicity of nanoparticles depends on multiple molecular and physicochemical mechanisms. Int J Mol Sci 18: 2702. https://doi.org/10.3390/ijms18122702
[131]	You DJ, Bonner JC (2020) Susceptibility factors in chronic lung inflammatory responses to engineered nanomaterials. Int J Mol Sci 21: 7310. https://doi.org/10.3390/ijms21197310
[132]	Singh A, Kukreti R, Saso L, et al. (2019) Oxidative stress: A key modulator in neurodegenerative diseases. Molecules 24: 1583. https://doi.org/10.3390/molecules24081583
[133]	Gänger S, Schindowski K (2018) Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics 10: 116. https://doi.org/10.3390/pharmaceutics10030116
[134]	Guo C, Xia Y, Niu P, et al. (2015) Silica nanoparticles induce oxidative stress, inflammation, and endothelial dysfunction in vitro via activation of the MAPK/Nrf2 pathway and nuclear factor-κB signaling. Int J Nanomedicine 10: 1463-1477. https://doi.org/10.2147/IJN.S76114
[135]	Uskoković V (2021) Nanomedicine for the poor: a lost cause or an idea whose time has yet to come?. Nanomedicine (Lond) 16: 1203-1218. https://doi.org/10.2217/nnm-2021-0024
[136]	Shubhika Kwatra (2013) Nanotechnology and medicine–The upside and the downside. Int. J Drug Dev Res 5: 1-10. http://www.ijddr.in
[137]	Diwan A, Tatake J, Chakraborty A (2022) Therapeutic uses of TheraCour™ polymeric nanomicelles against cancer, infectious diseases and more. Nanomaterials for Cancer Detection Using Imaging Techniques and Their Clinical Applications . Springer Nature 473-506. https://doi.org/10.1007/978-3-031-09636-5_17
[138]	Chakraborty A, Diwan A, Barton R, et al. (2022) A new antiviral regimen against sars-cov-2 based on nanoviricide's biopolymer (NV-CoV-2). Front Nanotechnol 4: 891605. https://doi.org/10.3389/fnano.2022.891605
[139]	Barton RW, Tatake JG, Diwan AR (2011) Nanoviricides-A novel approach to antiviral therapeutics. Bionanotechnology II . CRC Press 141-154.
[140]	Chakraborty A, Diwan A (2020) NL-63: A better surrogate virus for studying SARS-CoV-2. Integr Mol Med 7: 1-9. https://doi.org/10.15761/IMM.1000408
[141]	NanoViricides, Inc., Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre IND Application (2021). Available from: https://www.bloomberg.com/press-releases/2021-03-09/nanoviricides-inc-pan-coronavirus-covid-19-drug-candidates-are-highly-effective-in-pre-clinical-animal-studies-i.
[142]	Barton RW, Tatake JG, Diwan AR (2016) Nanoviricides: Targeted Anti-Viral Nanomaterials. Handbook of Clinical Nanomedicine, Nanoparticles, Imaging, Therapy, and Clinical Applications . Jenny Stanford Publishing 1039-1046.
[143]	NanoViricides is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 Virtual Conference (2020). Available from: https://www.accesswire.com/604794/NanoViricides-is-Developing-Drugs-Against-SARS-CoV-2-with-an-Integrated-Approach-to-Combat-COVID-19-as-Reported-at-The-LD-500-Virtual-Conference.
[144]	Pal M, Berhanu G, Desalegn C, et al. (2020) Severe acute respiratory syndrome coronavirus-2 (sars-cov-2): an update. Cureus 12: e7423. https://doi.org/10.7759/cureus.7423
[145]	Chatterjee S, Bhattacharya M, Nag S, et al. (2023) A detailed overview of sars-cov-2 omicron: its sub-variants, mutations and pathophysiology, clinical characteristics, immunological landscape, immune escape, and therapies. Viruses 15: 167. https://doi.org/10.3390/v15010167
[146]	Beigel JM, Tomashek KM, Dodd LE, et al. (2020) Remdesivir for the treatment of Covid-19 final report. N Engl J Med 83: 1813-1826. https://doi.org/10.1056/NEJMoa2007764
[147]	ClinicalTrials.gov, multicenter, retrospective study of the effects of remdesivir in the treatment of severe Covid-19 infections, 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04365725
[148]	Chakraborty A, Diwan A, Arora V, et al. (2022) Polymer protects the drug and improves its pharmacokinetics. EC Pharmacol Toxicol 10.2: 108-118. https://ecronicon.org/assets/ecpt/pdf/ECPT-10-00707.pdf
[149]	Osorno LL, Brandley AN, Maldonado DE, et al. (2021) Review of contemporary self-assembled systems for the controlled delivery of therapeutics in medicine. Nanomaterials (Basel) 11: 278. https://doi.org/10.3390/nano11020278
[150]	Yadav S, Sharma AK, Kumar P (2020) Nanoscale self-assembly for therapeutic delivery. Front Bioeng Biotechnol 8: 127. https://doi.org/10.3389/fbioe.2020.00127
[151]	Li H, Labean TH, Leong KW (2011) Nucleic acid-based nanoengineering: novel structures for biomedical applications. Interface Focus 1: 702-24. https://doi.org/10.1098/rsfs.2011.0040
[152]	Marshall ML, Wagstaff KM (2020) Internalized functional DNA aptamers as alternative cancer therapies. Front Pharmacol 11: 1115. https://doi.org/10.3389/fphar.2020.01115
[153]	Ni X, Castanares M, Mukherjee A, et al. (2011) Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 18: 4206-14. https://doi.org/10.2174/092986711797189600
[154]	Li J, Mo L, Lu CH, et al. (2016) Functional nucleic acid-based hydrogels for bioanalytical and biomedical applications. Chem Soc Rev 45: 1410-31. https://doi.org/10.1039/C5CS00586H
[155]	Abune L, Wang Y (2021) Affinity hydrogels for protein delivery. Trends Pharmacol Sci 42: 300-312. https://doi.org/10.1016/j.tips.2021.01.005

Reader Comments

Your name:*

Email:*
© 2023 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

AIMS Microbiology

4.1 4.9

Metrics

Article views(2460) PDF downloads(187) Cited by(5)

Preview PDF

Download XML

Export Citation

Article outline

Show full outline

AIMS Microbiology

Prospect of nanomaterials as antimicrobial and antiviral regimen

Related Papers:

Abstract

1. Introduction

2. Model and methods

2.1. Model

2.2. Methods

3. Results and discussion

4. Conclusions

References

Reader Comments

通讯作者: 陈斌, bchen63@163.com

Metrics

Figures and Tables

Other Articles By Authors

Catalog

Abstract

1. Introduction

2. Model and methods

2.1. Model

2.2. Methods

3. Results and discussion

4. Conclusions

References

AIMS Microbiology

Prospect of nanomaterials as antimicrobial and antiviral regimen

Related Papers:

Abstract

1. Introduction

2. Model and methods

2.1. Model

2.2. Methods

3. Results and discussion

4. Conclusions

References

Reader Comments

通讯作者: 陈斌, bchen63@163.com

Metrics

Figures and Tables

Other Articles By Authors

Related pages

Tools

Export File

Citation

Format

Content

Catalog

Abstract

1. Introduction

2. Model and methods

2.1. Model

2.2. Methods

3. Results and discussion

4. Conclusions

References